Advicenne obtains Orphan Drug Designation for ADV7103 in the United States for the treatment of distal Renal Tubular Acidosis (dRTA)

Dec 13, 2022

Advicenne obtains Orphan Drug Designation for ADV7103 in the United States for the treatment of distal Renal Tubular Acidosis (dRTA)

Retour aux communiqués de presse
Back to press releases
Ouvrir le document
Open the file